Publications

Export 111 results:
Sort by: [ Author  (Asc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
G
Goubran, H., G. Ragab, and S. Hassouna, Precision Anticoagulation Medicine: A Practical Guide, : Springer Nature, 2019. Abstract
n/a
Goubran, H., J. Stakiw, J. Seghatchian, G. Ragab, and T. Burnouf, "SARS-CoV-2 and cancer: The intriguing and informative cross-talk", Transfusion and Apheresis Science: Elsevier Ltd, 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Goubran, H., G. Ragab, and W. Sabry, "Metabolism-mediated thrombotic microangiopathy and B12", Vitamins and Hormones, vol. 119: Academic Press Inc., pp. 441 - 455, 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Group, G. E. O. - R. A., C. Ramos-Remus, A. Ramirez-Gomez, V. Brambila-Barba, A. Barajas-Ochoa, J. D. Castillo-Ortiz, A. O. Adebajo, L. R. Espinoza, F. J. Aceves-Avila, J. M. Sánchez-González, et al., "Latitude gradient influences the age of onset of rheumatoid arthritis: a worldwide survey", Clinical Rheumatology, vol. 36, issue 3: Springer London, pp. 485 - 497, 2017. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
H
Hamza, M. M. E., T. A. Macky, M. K. Sidky, G. Ragab, and M. M. Soliman, "Intravitreal infliximab in refractory uveitis in Behcet's disease: A safety and efficacy clinical study", Retina, vol. 36, issue 12: Lippincott Williams and Wilkins, pp. 2399 - 2408, 2016. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Hamza, M. M. E., T. A. Macky, M. K. Sidky, G. Ragab, and M. M. Soliman, "Intravitreal infliximab in refractory uveitis in Behçet's disease: a safety and efficacy clinical study", Retina, vol. 36, issue 12: LWW, pp. 2399-2408, 2016. Abstract
n/a
Hegab, M. M., A. F. Abdelwahab, J. M. Rudolph, A. E. - S. M. Yousef, M. N. Salem, W. El-Baz, S. Abdelrhman, F. Elshabacy, A. Alhefny, and W. Abouraya, "Corrigendum to" CD28 and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians"[Hum. Immunol. 77 (2016) 522-526]", Human immunology, vol. 78, issue 7-8, pp. 521, 2017. Abstract
n/a
Hegab, M. M., A. F. Abdelwahab, J. M. Rudolph, A. M. El-Sayed Yousef, M. N. Salem, W. El-Baz, S. Abdelrhman, F. Elshabacy, A. Alhefny, W. Abouraya, et al., "Corrigendum to “CD28 and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians” [Hum. Immunol. 77 (2016) 522–526] (S0198885916300684), (10.1016/j.humimm.2016.04.018))", Human Immunology, vol. 78, issue 7-8: Elsevier Inc., pp. 521, 2017. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Hegab, M. M., A. F. Abdelwahab, A. M. El-Sayed Yousef, M. N. Salem, W. El-Baz, S. Abdelrhman, F. Elshabacy, A. Alhefny, W. Abouraya, S. M. Ibrahim, et al., "CD28 and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians", Human Immunology, vol. 77, issue 6: Elsevier Inc., pp. 522 - 526, 2016. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Hegab, M. M., A. F. Abdelwahab, A. E. - S. M. Yousef, M. N. Salem, W. El-Baz, S. Abdelrhman, F. Elshabacy, A. Alhefny, W. Abouraya, and S. M. Ibrahim, "CD28 and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians", Human immunology, vol. 77, issue 6: Elsevier, pp. 522-526, 2016. Abstract
n/a
Hegab, M. M., A. F. Abdelwahab, J. M. Rudolph, A. M. El-Sayed Yousef, M. N. Salem, W. El-Baz, S. Abdelrhman, F. Elshabacy, A. Alhefny, W. Abouraya, et al., "Corrigendum to ?CD28 and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians? [Hum. Immunol. 77 (2016) 522?526] (S0198885916300684), (10.1016/j.humimm.2016.04.018))", Human Immunology, vol. 78, no. 7-8, 2017. Abstract
n/a
Hegab, M. M., A. F. Abdelwahab, A. M. El-Sayed Yousef, M. N. Salem, W. El-Baz, S. Abdelrhman, F. Elshabacy, A. Alhefny, W. Abouraya, S. M. Ibrahim, et al., "CD28 and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians.", Human immunology, vol. 77, issue 6, pp. 522-6, 2016 Jun. Abstract

OBJECTIVE: Limited data are available on the genetics of rheumatoid arthritis (RA) in Egyptians. Therefore, we investigated whether the confirmed genetic risk factors for RA in Europeans and/or Asians contribute to RA susceptibility in Egyptians.

SUBJECTS AND METHODS: A set of seven single-nucleotide polymorphisms (SNPs) in the vicinity of CD28, TNFAIP3, PTPN22, PADI4 and HLA-DRA were tested in a large multi-centric RA cohort in Egypt, consisting of 394 cases and 398 matched controls. Patients were stratified based on the positivity of either anti-citrullinated protein antibodies (ACPAs) or rheumatoid factor (RF).

RESULTS: Significant association was evident for three SNPs in this cohort: the CD28 (rs1980422) variant showed a strong association in the whole cohort (P=0.000119) and in seropositive subsets of the disease (PACPA+=0.004; PRF+=0.0005). Upon stratification, the PTPN22 (rs2476601) and TNFAIP3(rs5029939) variants showed association only with ACPA positive (PACPA+=0.00573) and negative (PACPA-=0.00999) phenotypes, respectively.

CONCLUSION: Our results suggest that CD28(rs1980422) and PTPN22(rs2476601) contribute to RA-susceptibility in Egyptians. Failure to replicate the association of PADI4(rs2240340)/(PADI4_94) in Egyptian RA patients provides further support for the notion that genetic architecture of RA is different in multiple populations of European, Asian, African, and Middle Eastern ancestries. Further investigation using large-scale studies is thus needed to maximize the power of genetic association.

Hegazy, M. T., M. A. Hussein, L. Quartuccio, M. Fawzy, N. Zoheir, M. I. Ellawindi, M. Bond, C. Mazzaro, A. E. Ray, and M. E. S. El Raziky, "Treatment of cryoglobulinemic vasculitis with sofosbuvir in four combination protocols", ARTHRITIS & RHEUMATOLOGY, vol. 68: WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, 2016. Abstract
n/a
Hegazy, M. T., W. R. Allam, M. A. Hussein, N. Zoheir, L. Quartuccio, S. F. El-Khamisy, and G. Ragab, "Increased genomic instability following treatment with direct acting anti-hepatitis C virus drugs", EBioMedicine, vol. 35: Elsevier, pp. 106-113, 2018. Abstract
n/a
Hegazy, M. T., A. Fayed, T. El Shabony, M. Visentini, D. Saadoun, P. Cacoub, and G. Ragab, "Relapsing Cryoglobulinemic Vasculitis Following Successful HCV Eradication by Interferon-Free Direct Acting Antivirals, an International Multicenter Study", ARTHRITIS & RHEUMATOLOGY, vol. 71: WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, 2019. Abstract
n/a
Hegazy, M. T., W. R. Allam, M. A. Hussein, N. Zoheir, L. Quartuccio, S. F. El-Khamisy, G. Ragab, and M. C. C. the for the study of Vasculitis, "Increased genomic instability following treatment with direct acting anti-hepatitis C virus drugs", EBioMedicine, vol. 35: Elsevier B.V., pp. 106 - 113, 2018. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Hussein, M., A. El-Hindawi, and G. Ragab, "Everolimus in Erdheim–Chester disease", The Egyptian Journal of Internal Medicine, vol. 25, issue 3, pp. 159 - 163, 2013/9/1. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ

A 43-year-old man presented with bony pains, repeated pathological fractures with overlying skin ulcerations, and forearm and chest wall swellings. Investigations led to the diagnosis of Erdheim–Chester disease. Treatment with low-dose prednisolone, oral everolimus, and zoledronic acid was started, with a marked improvement in his condition.

Hussein, M., M. Ellawindi, and G. Ragab, "Performance of classification criteria for Behcet's disease in an Egyptian cohort", Indian Journal of Rheumatology, vol. 12, issue 3: Medknow Publications, pp. 152 - 155, 2017. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Hussein, M. A., M. I. Ellawindi, and G. Ragab, "Performance of classification criteria for Behcet's disease in an Egyptian cohort", Indian Journal of Rheumatology, vol. 12, issue 3: Medknow Publications, pp. 152, 2017. Abstract
n/a
Hussein, M. A., A. El-Hindawi, and G. Ragab, "Everolimus in Erdheim–Chester disease", The Egyptian Journal of Internal Medicine, vol. 25, issue 3: SpringerOpen, pp. 159-163, 2013. Abstract
n/a
L
Luca, Q., I. Miriam, C. Laura, R. Soledad, M. A. M. El Menyawi, G. Elisa, M. Sebastiani, P. Nicolo, U. Teresa, and C. Vincenza, "Validation Study Of The International Classification Criteria For The Cryoglobulinemic Vasculitis", ACR 2013 ANNUAL MEETING, vol. 65, pp. S1123-S1124, 2013. Abstract
n/a
M
M Fawzy, A Edrees, O. E. A. R. H. A. G., "Gastrointestinal manifestations in systemic lupus erythematosus", Lupus, 2016. Abstract
n/a
Mattar, M., H. M. A. Ahmed, and G. Ragab, "Antiphospholipid Syndrome", Precision Anticoagulation Medicine: Springer, Cham, pp. 181-201, 2020. Abstract
n/a
H
Hegazy, M. T., W. R. Allam, M. A. Hussein, N. Zoheir, L. Quartuccio, S. F. El-Khamisy, and G. Ragab, "Increased genomic instability following treatment with direct acting anti-hepatitis C virus drugs.", EBioMedicine, vol. 35, pp. 106-113, 2018 Sep. Abstract

Mixed Cryoglobulinemic Vasculitis (MCV) is a prominent extra-hepatic manifestation of Hepatitis C virus (HCV) infection. HCV has been reported to cause B-cell disorders and genomic instability. Here, we investigated B-cell activation and genome stability in HCV-MCV patients receiving the direct antiviral agent, Sofosbuvir, at multiple centers in Egypt. Clinical manifestations in HCV-MCV patients were improved at the end of treatment (EOT), such as purpura (100%), articular manifestations (75%) and neuropathy (68%). Eighteen patients (56%) showed vasculitis relapse after EOT. BAFF and APRIL were higher at EOT and continued to increase one year following treatment onset. Chromosomal breaks were elevated at EOT compared to baseline levels and were sustained at 3 and 6 months post treatment. We report increased expression of DNA genome stability transcripts such as topoisomerase 1 and TDP1 in HCV-MCV patients after treatment, which continued to increase at 12 months from treatment onset. This data suggest that B-cell activation and DNA damage are important determinants of HCV-MCV treatment outcomes.

M
Moawad, P., R. Shamma, D. Hassanein, G. Ragab, and O. El Zawahry, "Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome", European Journal of Ophthalmology, vol. 32, issue 1: SAGE Publications Ltd, pp. 673 - 679, 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
P
Pusiol, A., F. Marzona, D. Cucchiaro, L. Castriotta, S. Usai, M. Narduzzi, C. Pilotto, I. Liguoro, R. Tosolini, and E. Passone, "Articles online first", Minerva Pediatrica, 2020. Abstract
n/a
Q
Quartuccio, L., L. Corazza, M. Ramos-Casals, S. Retamozo, G. M. Ragab, G. Ferraccioli, E. Gremese, A. Tzioufas, M. Voulgarelis, D. Vassilopoulos, et al., "OP0274 Cryoglobulinemic Vasculitis and Primary sjögren's Syndrome are Independent Risk Factors for Lymphoma in a Large Worldwide Population of Patients with Positive Serum Cryoglobulins", Annals of the Rheumatic Diseases, vol. 74, issue Suppl 2, pp. 175-176, June 1, 2015. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ

Background Serum cryoglobulins (SC) may be found in many diseases (1), and the presence of serum cryoglobulins is a known risk factor for lymphoma evolution in some non malignant diseases.Objectives The aim of this study was to distiguish the role of cryoglobulinemic vasculitis (CV), classified according to the recent validated criteria (1,2), and primary Sjögren's syndrome (pSS) as risk factors of lymphoma in patients positive serum cryoglobulins. Importantly, SC, CV and pSS may occur together.Methods 950 charts from consecutive patients with positive SC were evaluated. Patients carrying both pSS and HCV infection, as well as incomplete charts, were excluded.Results 657 patients with SC were selected, 374 with CV and 283 without CV, according to the published criteria (2,3). PSS, classified according to the American-European Group Criteria was present in 96 patients (44 with CV, 52 without). Lymphoma was reported in 61/657 (9.8%) patients with SC. Among them, CV was present in 44/61 (72,1%; 14 also with pSS), and pSS in 17/61 (27,9%; and 14/17 had CV). Patients with SC with CV showed an higher prevalence of lymphoma than patients with SC without CV (44/374, 11.5% vs.17/283, 6.3%; p=0.025, OR=1.93 [95%IC: 1.08-3.39]. Patients with pSS, SC and CV also showed a higher prevalence of lymphoma than patients with pSS, SC but without CV (14/44, 31.8% vs. 3/52, 7.4%; p=0.001, OR=7.62 [95%CI 2.02-28.74]. CV and pSS were confirmed as independent risk factor for lymphoma by multivariate analysis (OR 2,18 95%CI 1,18-3,83, p=0,012; OR 2,65 95%CI 1,04-6,76, p=0,042, respectively). Infection by the hepatitis C virus (HCV) was detected in 467/561 (83,2%) patients with SC without pSS, and did not statistically predispose to lymphoma when associated with CV in this subset (p=1,0).Conclusions Cryoglobulinemic vasculitis and pSS are independent risk factors for lymphoma in patients with evidence of SC. Patients with both the conditions (CV and pSS) have the highest risk. In the follow-up of SC positive patients, a very high attention should be deserved to pSS, in particular when CV is present.ReferencesDe Vita S, et al. Ann Rheum Dis. 2011; 2) Quartuccio L, et al. Rheumatology (Oxford). 2014Disclosure of Interest None declared

Quartuccio, L., M. Isola, L. Corazza, M. Ramos-Casals, S. Retamozo, G. M. Ragab, M. N. Zoheir, M. A. - M. El-Menyawi, M. N. Salem, and D. Sansonno, "Validation of the classification criteria for cryoglobulinaemic vasculitis", Rheumatology, vol. 53, issue 12: Oxford University Press, pp. 2209-2213, 2014. Abstract
n/a
Quartuccio, L., M. Isola, L. Corazza, S. Retamozo, M. A. - M. El-Menyawi, E. Gremese, M. Sebastiani, N. Pipitone, T. Urraro, V. Conteduca, et al., "Validation Study Of The International Classification Criteria For The Cryoglobulinemic Vasculitis", ARTHRITIS AND RHEUMATISM, vol. 65, pp. S1123–S1124, 2013. Abstract
n/a
Quartuccio, L., M. Isola, L. Corazza, M. Ramos-Casals, S. Retamozo, G. M. Ragab, M. N. Zoheir, M. A. - M. El-Menyawi, M. N. Salem, D. Sansonno, et al., "Validation of the classification criteria for cryoglobulinaemic vasculitis.", Rheumatology (Oxford, England), vol. 53, issue 12, pp. 2209-13, 2014 Dec. Abstract

OBJECTIVE: The aim of this study was to validate the classification criteria for cryoglobulinaemic vasculitis (CV).

METHODS: Twenty-three centres were involved. New patients with CV (group A) and controls, i.e. subjects with serum cryoglobulins but lacking CV based on the gold standard of clinical judgment (group B) and subjects without cryoglobulins but with clinical features that can be observed in the course of CV (group C), were studied. Positivity of serum cryoglobulins was necessary for CV classification. Sensitivity and specificity of the criteria were calculated by comparing group A vs group B. The group A vs group C comparison was done to demonstrate the possible diagnostic utility of the criteria.

RESULTS: The study included 268 patients in group A, 182 controls in group B and 193 controls in group C (small vessel vasculitis, 51.8%). The questionnaire (at least 2/3 positive answers) showed 89.0% sensitivity and 93.4% specificity; the clinical item (at least 3/4 clinical involvement) showed 75.7% sensitivity and 89.0% specificity and the laboratory item (at least 2/3 laboratory data) showed 80.2% sensitivity and 62.4% specificity. The sensitivity and specificity of the classification criteria (at least 2/3 positive items) were 89.9% and 93.5%, respectively. The comparison of group A with group C demonstrated the clinical utility of the criteria in differentiating CV from CV mimickers.

CONCLUSION: Classification criteria for CV were validated in a second, large, international study confirming good sensitivity and specificity in a complex systemic disease.

Quartuccio, L., M. Isola, L. Corazza, M. Ramos-Casals, S. Retamozo, G. M. Ragab, M. Naguib Zoheir, M. - M. El-Menyawi, M. N. Salem, D. Sansonno, et al., "Validation of the classification criteria for cryoglobulinaemic vasculitis", Rheumatology (United Kingdom), vol. 53, issue 12: Oxford University Press, pp. 2209 - 2213, 2014. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Quartuccio, L., L. Corazza, M. Ramos-Casals, S. Retamozo, G. M. Ragab, G. Ferraccioli, E. Gremese, A. Tzioufas, M. Voulgarelis, and D. Vassilopoulos, OP0274 Cryoglobulinemic Vasculitis and Primary sjögren's Syndrome are Independent Risk Factors for Lymphoma in a Large Worldwide Population of Patients with Positive Serum Cryoglobulins, : BMJ Publishing Group Ltd, 2015. Abstract
n/a
R
Ragab, G., M. T. Hegazy, M. Ali, M. R. E. Abdel-Halim, and X. Puéchal, "Three Patterns of Cutaneous Involvement in Granulomatosis with Polyangiitis", Journal of Advanced Research, vol. 24: Elsevier B.V., pp. 311 - 315, 2020. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Ragab, G., and M. A. Hussein, "Vasculitic syndromes in hepatitis C virus: A review", Journal of advanced research, vol. 8, issue 2: Elsevier, pp. 99-111, 2017. Abstract
n/a
Ragab, G., C. Dehner, H. Hamza, and M. Kriegel, "Systemic Lupus Erythematosus", The Microbiome in Rheumatic Diseases and Infection: Springer, 2018.
Ragab, G., W. Ruff, D. Pearson, H. Goubran, and M. Kriegel, "Antiphospholipid Syndrome", The Microbiome in Rheumatic Diseases and Infection: Springer, pp. 305-321, 2018. Abstract
n/a
Ragab, G., C. Dehner, H. Hamza, and M. Kriegel, "Systemic lupus erythematosus", The Microbiome in Rheumatic Diseases and Infection: Springer International Publishing, pp. 285 - 304, 2018. Abstract
n/a
Ragab, M., "Oral Direct Anticoagulants in Thrombosis Management in Anti-Phospholipid Syndrome: Unanswered Questions", J Hematol Thrombo Dis, vol. 3, issue 208: http://www.esciencecentral.org/journals/oral-direct-anticoagulants-in …, 2015. Abstract
n/a
Tourism